



**[1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES****Publication number:** WO03068776**Publication date:** 2003-08-21**Inventor:** IMMA HIRONORI (JP); WATANABE TOMOKAZU (JP); SHIOZAKI SHIZUO (JP); KANDA TOMOYUKI (JP); KUWANA YOSHIHISA (JP); SHIMADA JUNICHI (JP)**Applicant:** KYOWA HAKKO KOGYO KK (JP); IMMA HIRONORI (JP); WATANABE TOMOKAZU (JP); SHIOZAKI SHIZUO (JP); KANDA TOMOYUKI (JP); KUWANA YOSHIHISA (JP); SHIMADA JUNICHI (JP)**Classification:**

**- international:** **A61P3/10; A61P9/00; A61P9/10; A61P25/16; A61P25/24; A61P25/28; A61P43/00; C07D487/04; C07D519/00; A61P3/00; A61P9/00; A61P25/00; A61P43/00; C07D487/00; C07D519/00; (IPC1-7): C07D487/04; A61K31/519; A61K31/5377; A61K31/5383; A61K31/542; A61P3/10; A61P9/00; A61P9/10; A61P25/16; A61P25/24; A61P25/28; A61P43/00; C07D519/00**

**- European:** C07D487/04; C07D519/00

**Application number:** WO2003JP01565 20030214**Priority number(s):** JP20020037819 20020215**Also published as:** AU2003211993 (A1)**Cited documents:** WO9842711 WO0017201**Report a data error here****Abstract of WO03068776**

[1,2,4]Triazolo[1,5-c]pyrimidine derivatives represented by the following general formula (I) or pharmacologically acceptable salts thereof which show an adenosine A2A receptor antagonism and are useful in treating and/or preventing various diseases caused by the hyperfunction of the adenosine A2A receptor: (I) wherein R1 represents optionally substituted aryl or optionally substituted heteroaryl; R2 represents hydrogen, halogeno, optionally substituted lower alkyl, optionally substituted aryl or optionally substituted heteroaryl; and R3 represents a group of any of the following formulae (A), (B) and (C).

---

Data supplied from the **esp@cenet** database - Worldwide